PIXATIMOD

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C51H88O60S13
Molecular Weight	2078.053
Optical Activity	UNSPECIFIED
Defined Stereocenters	29 / 29
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](COS(O)(=O)=O)[C@@H](O[C@H]6O[C@H](COS(O)(=O)=O)[C@@H](O[C@H]7O[C@H](COS(O)(=O)=O)[C@@H](O[C@H]8O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]8OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]7OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]6OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]5OS(O)(=O)=O

InChI

InChIKey=LNUFLCYMSVYYNW-ZPJMAFJPSA-N

InChI=1S/C51H88O60S13/c1-22(2)7-6-8-23(3)27-11-12-28-26-10-9-24-17-25(13-15-50(24,4)29(26)14-16-51(27,28)5)95-46-42(108-121(79,80)81)38(104-117(67,68)69)34(30(96-46)18-91-112(52,53)54)100-47-43(109-122(82,83)84)39(105-118(70,71)72)35(31(97-47)19-92-113(55,56)57)101-48-44(110-123(85,86)87)40(106-119(73,74)75)36(32(98-48)20-93-114(58,59)60)102-49-45(111-124(88,89)90)41(107-120(76,77)78)37(103-116(64,65)66)33(99-49)21-94-115(61,62)63/h22-49H,6-21H2,1-5H3,(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H,88,89,90)/t23-,24+,25+,26+,27-,28+,29+,30-,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47-,48-,49-,50+,51-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C51H88O60S13
Molecular Weight	2078.053
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	29 / 29
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800019929 | https://www.ncbi.nlm.nih.gov/pubmed/21285983 | https://www.ncbi.nlm.nih.gov/pubmed/22101246 | https://www.ncbi.nlm.nih.gov/pubmed/29531325

PG-545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG-545 also inhibits heparanase, the only endoglycosidase which cleaves HS chains in the ECM. The anti- respiratory syncytial virus (RSV) activity of PG-545 was due to both partial inhibition of the virus attachment to cells and a more profound interference with some post-attachment steps as PG-545 efficiently neutralized infectivity of the cell-adsorbed virus. The anti-RSV activity of PG-545 was reduced when tested in the presence of human nasal secretions. Serial passages of RSV in the presence of increasing concentrations of PG-545 selected for weakly resistant viral variants that comprised the F168S and the P180S amino acid substitutions in the viral G protein. PG-545 has an immunomodulatory properties. PG-545 stimulates innate immune responses against tumours in preclinical cancer models. PG-545 is in phase I clinical trial for the treatment of pancreatic cancer.

Originator

Approval Year

PubMed

Title	Date	PubMed
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.	2018-06-14	29898788
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.	2018-04	29531325
Prophylactic Antiheparanase Activity by PG545 Is Antiviral In Vitro and Protects against Ross River Virus Disease in Mice.	2018-04	29437628
Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth.	2017-08	28716813
Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545.	2017-05-23	28388547
The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.	2017-03	28147305
Heparanase Inhibition Reduces Glucose Levels, Blood Pressure, and Oxidative Stress in Apolipoprotein E Knockout Mice.	2017	29226146
The Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles.	2016-02	26643323
Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.	2016-01-19	26729870
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.	2016-01	26649979
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.	2015-05	25754234
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.	2015-03-10	25669977
PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.	2013-07	23696215
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.	2012-04-26	22458531
Potent anti-respiratory syncytial virus activity of a cholestanol-sulfated tetrasaccharide conjugate.	2012-01	22101246
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.	2012	23300607
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.	2011-02-15	21285983

Sample Use Guides

In Vivo Use Guide

25, 50, 100 and 150 mg once weekly for 28 days

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Tue Apr 01 17:31:58 GMT 2025` Edited by `admin` on `Tue Apr 01 17:31:58 GMT 2025`
Record UNII	66QR34C83N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIXATIMOD

Official Name

English

PG-545 FREE ACID

Preferred Name

English

Pixatimod [WHO-DD]

Common Name

English

pixatimod [INN]

Common Name

English

Code System Code Type Description

PUBCHEM

57412325